证券代码：600513 股票简称：联环药业 公告编号：2025—058 江苏联环药业股份有限公司 关于全资子公司收到药品GMP符合性检查结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 注： 1、以上数据来源为国家药品监督管理局官方网站； 2、上述统计结果可能不尽完善，仅供参考； | 企业名称 | 联环药业（安庆）有限公司 | 药品生产许可证号 | 皖 20250621 | | --- | --- | --- | --- | | 检查地址 | 安徽省安庆市高新区霞虹路 | 18 号 | | | 检查范围及相 | 检查范围 | 车间 | 生产线 | | 关车间、生产线 | 口服溶液剂 | 制剂车间 | 口服溶液 1 号 生产线 | | 检查依据 | 《中华人民共和国药品管理法》《药品生产监督管理办法》《药品生产质 量管理规范(2010 年修订)》《关于加强药品上市许可持有人委托生产监督 管理工作的公告》《药品上市许可持有人委托生产现场检查指南》《药品 | | | | 检查时间 | 检查管理办法（试行）》 2025 年 ...

Core Viewpoint - Lianhuan Pharmaceutical's subsidiary, Lianhuan (Anqing), has successfully passed the GMP compliance inspection for its newly established oral solution production line, indicating its capability to meet pharmaceutical quality standards and fulfill market demand [1] Group 1: GMP Compliance and Production Capacity - Lianhuan (Anqing) received the GMP compliance inspection notice from the Anhui Provincial Drug Administration, marking the first successful inspection since the establishment of the oral solution production line [1] - The successful GMP compliance indicates that Lianhuan (Anqing) has officially acquired the production capacity that meets pharmaceutical quality requirements, laying a solid foundation for meeting market demand [1] Group 2: Financial Investment and Stock Performance - The investment in the oral solution production line amounts to approximately 7.5 million yuan (unverified data) [1] - Lianhuan Pharmaceutical's stock price has seen a significant increase, reaching a historical high of 29.47 yuan per share on August 19, with a rise of 6.08% on that day [1]

Core Insights - Lianhuan Pharmaceutical (600513.SH) announced that its wholly-owned subsidiary, Lianhuan (Anqing), has received the "Drug GMP Compliance Inspection Notification" from the Anhui Provincial Drug Administration [2] - This inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval Number H20243410) and marks the first successful GMP compliance inspection for the newly established oral solution production line [2] - The investment in the oral solution production line amounts to approximately 7.5 million yuan [2]

Group 1 - The company announced that its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., received a notice of compliance inspection for drug GMP from the Anhui Provincial Drug Administration [1] - The inspection will focus on the oral solution dosage form, specifically the production line for oral solution No. 1, scheduled from June 4 to June 7, 2025 [1] - The inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval No. H20243410) [1] Group 2 - As of the announcement date, the investment in the oral solution production line amounts to approximately RMB 7.5 million [1]

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) has successfully passed the GMP compliance inspection for its newly established oral solution production line, indicating its capability to meet drug quality requirements and support market demand [1] Summary by Relevant Sections - **GMP Compliance Inspection** - Lianhuan Pharmaceutical (Anqing) Co., Ltd. received the GMP compliance inspection notice from the Anhui Provincial Drug Administration, marking the first successful inspection of the new oral solution production line [1] - **Investment in Production Line** - The investment in the oral solution production line amounts to approximately RMB 7.5 million, with the data being unaudited [1] - **Production Capability** - The successful GMP compliance inspection signifies that Lianhuan (Anqing) has officially established production capabilities that meet drug quality standards, laying a solid foundation to meet market demand for related drugs [1] - **Impact on Company Performance** - The GMP compliance inspection results are not expected to have a significant impact on the company's performance [1]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant stock price increase and strong revenue growth, indicating a positive market response and operational performance despite a decline in net profit [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise [1] - The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules, suppositories, and granules, with an annual production capacity of 5 billion units [1] - Its main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties, including key products like the first-class new drug Aipulete and second-class new drug Ebastine [1] - The company boasts a high-end R&D team of nearly 200 members and multiple research platforms [1] Financial Performance - For the period from January to March 2025, the company achieved a revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1] - The net profit attributable to shareholders was 23.06 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders was 30,300, with an average of 9,416 circulating shares per person [1] Market Activity - On August 19, the company's stock price increased by 7.42%, reaching 29.84 yuan per share, with a trading volume of 699 million yuan and a turnover rate of 8.57% [1] - The total market capitalization of Jiangsu Lianhuan Pharmaceutical is 8.518 billion yuan [1]

7月15日公司发布上半年业绩预告，预计实现净利润-4500.00万元至-3800.00万元，同比变动区间 为-171.56%~-160.42%。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计显示，联环药业所属的医药生物行业，目前整体涨幅为1.44%，行业内，目前股价 上涨的有438只，涨停的有福瑞股份、济民健康等3只。股价下跌的有48只，跌幅居前的有南模生物、皓 宸医疗、广誉远等，跌幅分别为4.23%、4.01%、3.62%。 公司发布的一季报数据显示，一季度公司共实现营业收入6.28亿元，同比增长18.78%，实现净利润 2305.96万元，同比下降29.15%，基本每股收益为0.0800元，加权平均净资产收益率1.64%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 联环药业股价再创历史新高，该股近期呈不断突破新高之势，近一个月累计有10个交易日股价刷新历史 纪录。截至09:40，该股目前上涨2.66%，股价报28.52元，成交1131.11万股，成交金额3.15亿元，换手 率3.96%，该股最新A股总市值达81.41亿元，该股A股流通市值81.41亿元。 ...

Group 1 - The stock price of Lianhuan Pharmaceutical is reported at 25.05 yuan, down 1.02 yuan from the previous trading day [1] - The stock opened at 25.38 yuan, reached a high of 26.74 yuan, and a low of 25.01 yuan, with a total trading volume of 1.199 billion yuan [1] - Lianhuan Pharmaceutical operates in the chemical pharmaceutical sector, with business activities including innovative drug research and development [1] Group 2 - The company has a total market capitalization of 7.151 billion yuan, with circulating market value equal to total market value [1] - On August 14, the stock experienced rapid fluctuations, with a rebound of over 2% within 5 minutes at 9:37 AM, followed by a decline of over 2% within 5 minutes at 9:42 AM [1] - The net outflow of main funds on that day was 161 million yuan, accounting for 2.25% of the circulating market value, with a cumulative net outflow of 95.3544 million yuan over the past five trading days, representing 1.33% of the circulating market value [1]

证券代码：600513 证券简称：联环药业 公告编号：2025—057 江苏联环药业股份有限公司 股票交易异常波动的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、江苏联环药业股份有限公司（以下简称"公司"）股票于 2025 年 8 月 8 日、8 月 11 日、8 月 12 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 2、经公司自查并书面征询公司控股股东和实际控制人，截至本公告披露日， 控股股东及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资 产重组、股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业 务合作、引进战略投资者等重大事项。 3、公司 2025 年半年度实现归属于上市公司股东的净利润区间预计为 -4,500.00 万元人民币至-3,800.00 万元人民币，与上年同期相比将减少 10,088.79 万元人民币到 10,788.79 万元人民币，业绩由盈转亏。 4、公司股票价格自 2025 ...

关于江苏联环药业股份有限公司股票交易 异常波动询证函的回复 我公司在本次股票异常波动期间未买卖联环药业股票。 江苏联环药业集团有限公司 江苏联环药业股份有限公司: 《江苏联环药业股份有限公司关于公司股票交易异常 波动的询证函》收悉,经自查确认,现回复如下: 我公司作为江苏联环药业股份有限公司（以下简称"联" 环药业")的控股股东,截至目前,除联环药业在指定媒体 已披露信息之外,我公司不存在影响联环药业股票价格异常 波动的重大事项;不存在应披露而未披露的重大信息,包括 但不限于重大资产重组、股份发行、上市公司收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、 引进战略投资者等重大事项。 同时,经与扬州市国有资产监督管理委员会(以下简称 "扬州市国资委")确认,截至目前,扬州市国资委作为联 环药业的实际控制人,除联环药业在指定媒体已披露信息之 外,扬州市国资委不存在影响联环药业股票价格异常波动的 重大事项;不存在应披露而未披露的重大信息,包括但不限 于重大资产重组、股份发行、上市公司收购、债务重组、业 务重组、资产剥离、资产注入、股份回购、股权激励、引进 战略投资者等重大事项。 我公司亦将严格遵 ...